Atossa Therapeutics Reports Positive Results from KARISMA Endoxifen Trial for Breast Cancer Risk Reduction

Atossa Therapeutics, Inc. unveils significant findings from the Phase 2 KARISMA Endoxifen trial, aligning with its commitment to developing innovative treatments for breast cancer. The trial, which involved 240 healthy premenopausal women, focuses on the impact of daily oral (Z)-endoxifen on mammographic breast density (MBD), a crucial risk factor for breast cancer. The results indicate both 1 mg and 2 mg doses of Endoxifen lead to significant reductions in MBD after six months, with an impressive 19.3% reduction from the 1 mg dose and a 26.5% reduction from the 2 mg dose, both statistically significant compared to placebo.

Effective Results and Tolerability Profile

The findings are particularly notable as they demonstrate that the 1 mg dose has a tolerability profile akin to that of a placebo, indicating its potential as a risk-reduction therapy for women at high risk of breast cancer. The trial reports minimal adverse effects, with a slight increase in events among the 2 mg dosage group, but without clinically significant safety issues. This favorable profile positions Endoxifen as a viable preventive treatment option in at-risk populations, with reductions in MBD comparable to traditional therapies like tamoxifen.

Broader Implications for Atossa Therapeutics

The study, appearing in the Journal of the National Cancer Institute and funded by Atossa, reinforces the company’s strategy in oncology. As part of a broader development plan, Atossa continues to explore applications for (Z)-endoxifen beyond breast cancer, including treatments for rare diseases such as Duchenne Muscular Dystrophy and McCune-Albright Syndrome. This comprehensive approach highlights Atossa's ongoing commitment to addressing unmet needs in healthcare, aiming to enhance therapeutic options for patients.

Commitment to Innovative Healthcare Solutions

As Atossa Therapeutics forges ahead, it not only strengthens its pipeline through promising studies but also reaffirms its dedication to improving patient outcomes in oncology and rare diseases. With robust trial findings and ongoing research, the company is well-positioned to make impactful contributions to the medical community and the overall landscape of cancer risk reduction therapies.